News summarySEC EDGARNov 9, 2026, 12:00 PM
ImmunityBio, 8-K (2.02, 9.01): reported results of operations
ImmunityBio reported third-quarter 2026 net product revenue of $48.7 million, up 53% year over year, nine-month revenue of $143.6 million, up 92%, and FDA and Israeli approvals expanding ANKTIVA’s use in bladder cancer.